Sage Therapeutics Inc $ 50.7 0.91 (1.83%)
Volume:
582,761
Avg Vol (1m):
745,640
Market Cap $:
2.63 Bil
Enterprise Value $:
1.79 Bil
P/E (TTM):
0.00
P/B:
3.09
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 24.78 | ||
| Equity-to-Asset | 0.9 | ||
| Debt-to-Equity | 0.04 | ||
| Debt-to-EBITDA | -0.05 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 12.39 | ||
| Beneish M-Score | -6.08 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -7709.7 | ||
| Net Margin % | -7406.74 | ||
| ROE % | -59.62 | ||
| ROA % | -53.89 | ||
| ROC (Joel Greenblatt) % | -1531.71 | ||
| 3-Year EBITDA Growth Rate | -42.7 | ||
| 3-Year EPS without NRI Growth Rate | -41.2 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 3.09 | ||
| PS Ratio | 301.8 | ||
| EV-to-EBIT | -2.68 | ||
| EV-to-EBITDA | -2.69 | ||
| EV-to-Revenue | 206.54 | ||
| Current Ratio | 12.77 | ||
| Quick Ratio | 12.77 | ||
| Days Payable | 5065.18 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.1 | ||
| Earnings Yield (Greenblatt) % | -37.31 |